Condition: Tuberculosis · Sponsor: Huashan Hospital
This study is a randomized controlled trial among asymptomatic tuberculosis individuals aiming to assess whether the standard treatment duration can be shortened to 17 weeks without increasing the types or doses of anti-tuberculosis medications or 13 weeks with the high-dose rifapentine and moxifloxacin.
This description comes directly from the study's public registry record.
Yang Li, Dr. · (086)18817583793 · y_li11@fudan.edu.cn
Always discuss trial participation with your own doctor first.
| Beijing Chest Hospital, Capital Medical University | Beijing, Beijing Municipality, China | Recruiting |
| Liupanshui City Third People's Hospital | Liupanshui, Guizhou, China | Recruiting |
| Nayong County People's Hospital | Nayong, Guizhou, China | Recruiting |
| Huashan Hospital of Fudan University | Shanghai, Shanghai Municipality, China | Active Not Recruiting |
| The First People's Hospital of Linping District, Hangzhou | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06153069